Stock FATE FATE THERAPEUTICS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Financials Fate Therapeutics, Inc.

Equities

FATE

US31189P1021

Biotechnology & Medical Research

Market Closed - Nasdaq
Other stock markets
 21:00:00 26/04/2024 BST 		5-day change 1st Jan Change
3.8 USD -1.81% Intraday chart for Fate Therapeutics, Inc. -20.67% +1.60%
04-22 Fate Therapeutics, Inc. Announces Presentation of FT819 Proof-of-Concept Data for B cell-mediated Autoimmune Diseases at ASGCT Annual Meeting CI
03-21 Fate Therapeutics, Inc. announced that it has received $19.996366 million in funding from Redmile Group, LLC CI

Valuation

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Capitalization 1 1,479 7,933 5,587 980.4 368.8 432.5 - -
Enterprise Value (EV) 1 1,258 7,450 4,971 544.2 53.6 230.8 308.4 331.5
P/E ratio -13.6 x -43.3 x -26.1 x -3.47 x -2.28 x -2.04 x -2.24 x -2.1 x
Yield - - - - - - - -
Capitalization / Revenue 139 x 252 x 100 x 10.2 x 5.8 x 91.4 x 89.2 x 69.3 x
EV / Revenue 118 x 237 x 89 x 5.65 x 0.84 x 48.8 x 63.6 x 53.1 x
EV / EBITDA - - -23.5 x -1.85 x -0.31 x -1.08 x -1.42 x -1.39 x
EV / FCF -13.9 x -169 x -23.3 x -1.92 x -0.39 x -1.66 x -1.9 x -2.21 x
FCF Yield -7.2% -0.59% -4.3% -52.1% -258% -60.4% -52.7% -45.4%
Price to Book - - 8.25 x 2.03 x 0.98 x 1.62 x 1.52 x 2.39 x
Nbr of stocks (in thousands) 75,593 87,244 95,494 97,170 98,602 113,817 - -
Reference price 2 19.57 90.93 58.51 10.09 3.740 3.800 3.800 3.800
Announcement Date 02/03/20 24/02/21 28/02/22 28/02/23 26/02/24 - - -
1USD in Million2USD
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Net sales 1 10.68 31.43 55.85 96.3 63.53 4.729 4.85 6.24
EBITDA 1 - - -211.1 -294.6 -172.2 -213.4 -216.9 -239.3
EBIT 1 -100.7 -128.1 -217 -308.4 -190.5 -212 -220.7 -253.9
Operating Margin -943.14% -407.47% -388.56% -320.23% -299.86% -4,482.76% -4,549.58% -4,069.66%
Earnings before Tax (EBT) 1 -98.15 -173.4 -212.2 -281.7 -160.9 -195.1 -211.4 -251.8
Net income 1 -98.15 -173.4 -212.2 -281.7 -160.9 -195.1 -211.4 -251.9
Net margin -919% -551.59% -379.89% -292.55% -253.3% -4,126.05% -4,358.55% -4,036.21%
EPS 2 -1.440 -2.100 -2.240 -2.910 -1.640 -1.863 -1.699 -1.812
Free Cash Flow 1 -90.57 -44.16 -213.6 -283.8 -138.4 -139.3 -162.7 -150.3
FCF margin -848.03% -140.49% -382.43% -294.68% -217.86% -2,946.1% -3,353.95% -2,409.19%
FCF Conversion (EBITDA) - - - - - - - -
FCF Conversion (Net income) - - - - - - - -
Dividend per Share 2 - - - - - - - -
Announcement Date 02/03/20 24/02/21 28/02/22 28/02/23 26/02/24 - - -
1USD in Million2USD
Estimates

Income Statement Evolution (Quarterly data)

Fiscal Period: December 2021 Q3 2021 Q4 2022 Q1 2022 Q2 2022 Q3 2022 Q4 2023 Q1 2023 Q2 2023 Q3 2023 Q4 2024 Q1 2024 Q2 2024 Q3 2024 Q4 2025 Q1
Net sales 1 14.22 17.07 18.41 18.55 14.98 44.36 58.98 0.933 1.944 1.676 1.26 1.273 1.28 1.121 0.675
EBITDA 1 - - - - - - - - - -43.19 -49 -49.52 -50.05 - -
EBIT 1 -54.62 -69.38 -74.47 -83.11 -86.39 -64.42 -28.59 -62.56 -51.28 -48.08 -50.65 -52.5 -54.44 -54.45 -52.42
Operating Margin -383.99% -406.48% -404.4% -448.05% -576.67% -145.23% -48.48% -6,705.79% -2,637.81% -2,868.44% -4,019.52% -4,122.76% -4,252.84% -4,855.34% -7,766.12%
Earnings before Tax (EBT) 1 -43.31 -68.62 -65.69 -76.1 -83.56 -56.36 -18.88 -52.76 -45.17 -44.12 -46.81 -47.89 -49.18 -51.36 -51.81
Net income 1 -43.31 -68.62 -65.69 -76.1 -83.56 -56.36 -18.88 -52.76 -45.17 -44.12 -46.8 -47.89 -49.17 -51.32 -51.71
Net margin -304.45% -402.02% -356.74% -410.29% -557.79% -127.07% -32.01% -5,654.34% -2,323.56% -2,632.58% -3,714.13% -3,761.04% -3,841.19% -4,576.65% -7,661.11%
EPS 2 -0.4500 -0.7200 -0.6800 -0.7800 -0.8600 -0.5800 -0.1900 -0.5400 -0.4600 -0.4500 -0.4717 -0.4658 -0.4692 -0.4667 -0.4450
Dividend per Share - - - - - - - - - - - - - - -
Announcement Date 04/11/21 28/02/22 04/05/22 03/08/22 03/11/22 28/02/23 03/05/23 08/08/23 08/11/23 26/02/24 - - - - -
1USD in Million2USD
Estimates

Balance Sheet Analysis

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Net Debt 1 - - - - - - - -
Net Cash position 1 221 483 616 436 315 202 124 101
Leverage (Debt/EBITDA) - - - - - - - -
Free Cash Flow 1 -90.6 -44.2 -214 -284 -138 -139 -163 -150
ROE (net income / shareholders' equity) - - -39.9% -48.5% -37.8% -66% -90.4% -70.2%
ROA (Net income/ Total Assets) - - - - - - - -
Assets 1 - - - - - - - -
Book Value Per Share 2 - - 7.090 4.970 3.810 2.340 2.500 1.590
Cash Flow per Share 2 - - -1.720 -2.560 -1.340 -1.900 -1.500 -
Capex 1 7.4 4.93 50.7 35.6 6.15 4 8.67 12
Capex / Sales 69.24% 15.69% 90.79% 36.93% 9.68% 84.58% 178.69% 192.31%
Announcement Date 02/03/20 24/02/21 28/02/22 28/02/23 26/02/24 - - -
1USD in Million2USD
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Year-on-year evolution of the Yield

Change in Enterprise Value/EBITDA

Ratings for Fate Therapeutics, Inc.

Trading Rating
Investor Rating
ESG Refinitiv
C
More Ratings

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
20
Last Close Price
3.8 USD
Average target price
7.8 USD
Spread / Average Target
+105.26%
Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

1st Jan change Capi.
FATE THERAPEUTICS, INC. Stock Fate Therapeutics, Inc.
+1.60% 433M
VERTEX PHARMACEUTICALS INCORPORATED Stock Vertex Pharmaceuticals Incorporated
-2.31% 103B
REGENERON PHARMACEUTICALS, INC. Stock Regeneron Pharmaceuticals, Inc.
+0.56% 95.28B
ARGENX SE Stock argenx SE
+1.69% 22.15B
BIONTECH SE Stock BioNTech SE
-17.37% 21.02B
GENMAB A/S Stock Genmab A/S
-9.30% 18.15B
WUXI APPTEC CO., LTD. Stock WuXi AppTec Co., Ltd.
-41.01% 16.74B
BEIGENE, LTD. Stock BeiGene, Ltd.
-14.85% 16.05B
NEUROCRINE BIOSCIENCES, INC. Stock Neurocrine Biosciences, Inc.
+3.21% 13.68B
SAREPTA THERAPEUTICS, INC. Stock Sarepta Therapeutics, Inc.
+33.54% 12.17B
Bio Therapeutic Drugs
  1. Stock Market
  2. Equities
  3. FATE Stock
  4. Financials Fate Therapeutics, Inc.